Home Others Others Bisacodyl

research use only

Bisacodyl

Cat.No.S4047

Bisacodyl (INN) is a stimulant laxative drug that works directly on the colon to produce a bowel movement.
Bisacodyl Chemical Structure

Chemical Structure

Molecular Weight: 361.39

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: S404701 DMSO]72 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.9%
99.9

Chemical Information, Storage & Stability

Molecular Weight 361.39 Formula

C22H19NO4

 Storage (From the date of receipt)
CAS No. 603-50-9 Download SDF Storage of Stock Solutions

Synonyms N/A Smiles CC(=O)OC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC(=O)C)C3=CC=CC=N3

Solubility

In vitro
Batch:

DMSO : 72 mg/mL (199.23 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro
Bisacodyl (10 μg/mL) increases mRNA expression level of TNF-α, COX2 and PGE2 in Raw264.7 cells. [1]
In vivo
Bisacodyl (20 mg/kg) results in a decrease in AQP3 protein expression and increased mRNA expression level of TNF-α in the colon of rats. [1] This compound inhibits water absorption in rat jejunum, ileum, and colon, the degree of inhibition is linearly related to the logarithm of the bisacodyl concentration over the range of 0.05 mg to 2.0 mg per 100 mL. [2] This chemical (10 mg/kg, intragastrically) induces a significant decrease in jejunal NOS activity in rats. It (10 mg/kg, intragastrically) increases the distance traveled by the marker in all time periods. [3] It (5.9 mg/kg) decreases significantly jejunal and colonic (Na + K) ATPase activity as compared to saline-treated rats. This compound (5.9 mg/kg) increases significantly jejunal and colonic PGE2 content and stimulates jejunal and colonic adenyl cyclase activity as compared to those in control rats without affecting cAMP content. [4] It (4.3 mg/kg) coupled with AOM increases the number of crypt per focus, but not the number of tumors in rats. This chemical (43 mg/kg) significantly increases the number of crypt per focus and tumors in rats. [5]
References
  • [4] https://pubmed.ncbi.nlm.nih.gov/6249558/
  • [5] https://pubmed.ncbi.nlm.nih.gov/11693267/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06219707 Not yet recruiting
Irritable Bowel Syndrome With Constipation
Nanyang Technological University|National University of Singapore
 March 1 2024 Not Applicable
NCT05770960 Completed
Opioid-Induced Constipation
Universitaire Ziekenhuizen KU Leuven
 June 27 2018 Phase 4
NCT03279341 Completed
Chronic Constipation
University Hospital Gasthuisberg
 December 3 2012 Phase 4
NCT01424228 Completed
Constipation
Shire|Takeda
 April 6 2011 Phase 4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.